EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 25 / No 12 (Décembre 2009) Med Sci (Paris), 25 12 (2009) 999-1009 References
Free Access
Issue
Med Sci (Paris)
Volume 25, Number 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 999 - 1009
Section Un siècle d’histoire
DOI https://doi.org/10.1051/medsci/20092512999
Published online 15 December 2009
  1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256 : 495–7. [Google Scholar]
  2. Von Behring E, Kitasato S. Über das Zustandekommen der Diphterie-Immunität und der Tetanus-Immunität bei Thieren. Dtsch Med Wochenschr 1890; 49 : 1113–45. [Google Scholar]
  3. Roux E, Martin L, Chaillou A. Trois cents cas de diphtérie traités par le sérum antidiphtérique. Ann Inst Pasteur 1894; 8 : 640–61. [Google Scholar]
  4. Theakston RD, Warrell DA, Griffiths E. Report of a WHO workshop on the standardization and control of antivenoms. Toxicon 2003; 41 : 541–57. [Google Scholar]
  5. Rénon L. Deux cas de tétanos traités par des injections de sang antitoxique (méthode de MM. Behring et Kitasato). Ann Inst Pasteur 1892; 6 : 233–41. [Google Scholar]
  6. Roux E, Vaillard L. Contribution à l’étude du tétanos ; prévention et traitement par le sérum antitoxique. Ann Inst Pasteur 1893; 7 : 65–140. [Google Scholar]
  7. Smolens J, Vogt A, Crawford M, Stokes JJ. The persistence in the human circulation of horse and human tetanus antitoxins. J Pediatr 1961; 59 : 899–902. [Google Scholar]
  8. Rubbo SD, Suri JC. Passive immunization against tetanus with human immune globulin. Br Med J 1962; 2 : 79–81. [Google Scholar]
  9. Gibaldi M. Anatomy of an antibody, and related misadventures in developing an effective treatment for septic shock. Pharmacotherapy 1993; 13 : 302–8. [Google Scholar]
  10. Feldmann M, Maini RN. Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69 : 12–8. [Google Scholar]
  11. Maynard JA, Maassen CB, Leppla SH, et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat Biotechnol 2002; 20 : 597–601. [Google Scholar]
  12. Nowakowski A, Wang C, Powers D, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 2002; 99 : 11346–50. [Google Scholar]
  13. Héricourt J, Richet C. Technique des procédés pour obtenir du sérum pur de chien et innocuité des injections de ce liquide chez l’homme. CR Soc Biol 1891; 3 : 33–5. [Google Scholar]
  14. Héricourt J, Langlois P, Saint-Hilaire A. Effet thérapeutique des injections de sérum de chien (hémocyne) chez l’homme, dans le cours de la tuberculose. CR Soc Biol 1891; 3 : 45–53. [Google Scholar]
  15. Legrain E. Histoire d’une épidémie de typhus exanthématique ; essais de sérothérapie ; action bienfaisante des injections sous-cutanées de sérum de typhiques convalescents. Gaz Hôp 1895; 68 : 766–8. [Google Scholar]
  16. Debré R. La séroprophylaxie de la rougeole et ses applications pratiques. Monde Med 1925; 35 : 822–35. [Google Scholar]
  17. Metchnikoff E. Études sur la résorption des cellules. Ann Inst Pasteur 1899; 13 : 737–69. [Google Scholar]
  18. Brent L. A history of transplantation immunology. San Diego : Academic Press, 1997 : 247–65 et 319–20. [Google Scholar]
  19. Finn R, Clarke CA, Donohoe WT, et al. Experimental studies on the prevention of Rh haemolytic disease. Br Med J 1961; 1 : 1486–90. [Google Scholar]
  20. Kumpel BM. Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers. Vox Sang 2007; 93 : 99–111. [Google Scholar]
  21. Béliard R, Waegemans T, Notelet D, et al. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141 : 109–19. [Google Scholar]
  22. Cosimi AB, Burton RC, Colvin RB, et al. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody. Transplantation 1981; 32 : 535–9. [Google Scholar]
  23. Waldmann H. A personal history of the CAMPATH-1H antibody. Med Oncol 2002; 19 : S3–9. [Google Scholar]
  24. Press OW, Appelbaum F, Ledbetter JA, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987; 69 : 584–91. [Google Scholar]
  25. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83 : 435–45. [Google Scholar]
  26. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104 : 2635–42. [Google Scholar]
  27. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 9 : 754–8. [Google Scholar]
  28. Nopora A, Preiss S, Nicolini V, et al. Contribution of enhanced ADCC to superior in vivo efficacy of a novel type II humanized, third generation CD20 antibody (GA101) in NHL xenograft models. AACR Meeting Abstracts 2008 : 3991. [Google Scholar]
  29. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140 : 635–43. [Google Scholar]
  30. Héricourt J, Richet C. De la transfusion péritonéale, et de l’immunité qu’elle confère. CR Acad Sci 1888; 107 : 748–50. [Google Scholar]
  31. Héricourt J, Richet C. Traitement d’un cas de sarcome par la sérothérapie. CR Acad Sci 1895; 120 : 948–50. [Google Scholar]
  32. Héricourt J, Richet C. De la sérothérapie dans le traitement du cancer. CR Acad Sci 1895; 121 : 567–9. [Google Scholar]
  33. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982; 306 : 517–22. [Google Scholar]
  34. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89 : 4285–9. [Google Scholar]
  35. Soulillou JP, Peyronnet P, Le Mauff B, et al. Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet 1987; 1 :1339–42. [Google Scholar]
  36. Gold HK, Gimple LW, Yasuda T, et al. Pharmacodynamic study of F(ab’)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86 : 651–9. [Google Scholar]
  37. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44 : 1002–7. [Google Scholar]
  38. Lièvre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66 : 3992–5. [Google Scholar]
  39. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27 : 1122–9. [Google Scholar]
  40. Perez N, Le Deist F, Chatenoud L, et al. In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects. Bone Marrow Transplant 1989; 4 : 379–84. [Google Scholar]
  41. Antonyuk SV, Trevitt CR, Strange RW, et al. Crystal structure of human prion protein bound to a therapeutic antibody. Proc Natl Acad Sci USA 2009; 106 : 2554–8. [Google Scholar]
  42. Levites Y, Smithson LA, Price RW, et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models. FASEB J 2006; 20 : 2576–8. [Google Scholar]
  43. Yonehara S. Effects of anti-Fas antibodies on lymphocytes and other organs: preparation of original and new monoclonal antibodies and amelioration of systemic autoimmune disease. Int Rev Immunol 1999;18 : 329–45. [Google Scholar]
  44. Chatenoud L, Baudrihaye MF, Kreis H, et al. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody. Eur J Immunol 1982; 12 : 979–82. [Google Scholar]
  45. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7 : 622–32. [Google Scholar]
  46. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58 : 823–30. [Google Scholar]
  47. Hernández AM, Toledo D, Martínez D, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181 : 6625–34. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.